| Entry |
|
|---|
| Name |
Romosozumab (USAN);
Romosozumab (genetical recombination) (JAN)
|
|---|
| Formula |
C6452H9926N1714O2040S54
|
|---|
| Exact mass |
145785.0578
|
|---|
| Mol weight |
145875.6186
|
|---|
| Remark |
|
|---|
| Efficacy |
Osteoporosis agent, Sclerostin activity inhibitor |
|---|
| Comment |
Monoclonal antibody
Treatment of osteoporosis
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
M MUSCULO-SKELETAL SYSTEM
M05 DRUGS FOR TREATMENT OF BONE DISEASES
M05B DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
M05BX Other drugs affecting bone structure and mineralization
M05BX06 Romosozumab
D10156 Romosozumab (USAN)
Target-based classification of drugs [BR:br08310]
Not elsewhere classified
Signaling molecules
Wnt signaling
SOST
D10156 Romosozumab (USAN)
 |
|---|
| Other DBs |
|
|---|
| LinkDB |
 |
|---|
